Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Dull

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
JAMA|January 10, 2008
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trialMatthew D Snape, Kirsten P Perrett, Karen J Ford, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2014
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adultsHoan Jong Lee, Moon-Hyun Chung, Woo Joo Kim, et al.
Vaccine|January 24, 2026
Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccinesWilliam P Hausdorff, Marco Cavaleri, Marion F Gruber, et al.
The Journal of Infectious Diseases|December 14, 2004
Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 HajjPeter M Dull, Jalaa' Abdelwahab, Claudio T Sacchi, et al.
The Journal of Infectious Diseases|September 4, 2004
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthraxConrad P Quinn, Peter M Dull, Vera Semenova, et al.
Emerging Infectious Diseases|October 25, 2002
First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001Marc S Traeger, Steven T Wiersma, Nancy E Rosenstein, et al.
Vaccine|July 14, 2024
Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancerPeter M Dull, Sharon L Achilles, Rafi Ahmed, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
JAMA|January 10, 2008
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trialMatthew D Snape, Kirsten P Perrett, Karen J Ford, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2014
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adultsHoan Jong Lee, Moon-Hyun Chung, Woo Joo Kim, et al.
Vaccine|January 24, 2026
Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccinesWilliam P Hausdorff, Marco Cavaleri, Marion F Gruber, et al.
The Journal of Infectious Diseases|December 14, 2004
Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 HajjPeter M Dull, Jalaa' Abdelwahab, Claudio T Sacchi, et al.
The Journal of Infectious Diseases|September 4, 2004
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthraxConrad P Quinn, Peter M Dull, Vera Semenova, et al.
Emerging Infectious Diseases|October 25, 2002
First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001Marc S Traeger, Steven T Wiersma, Nancy E Rosenstein, et al.
Vaccine|July 14, 2024
Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancerPeter M Dull, Sharon L Achilles, Rafi Ahmed, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Pageof 5